Yi Zhang and shareholders representing over 59.2% of the outstanding shares of YS Biopharma Co., Ltd. (company or YS) announced the successful approval of all resolutions at the YS Extraordinary General Meeting of Shareholders (EGM) held on February 16, 2024. Immediately following the successful conclusion of the EGM, the new board of directors of the Company voted [unanimously] to effect the following resolutions (among others): the removal of Hui Shao from all positions with the Company and any subsidiaries of the company, including without limitation as chief executive officer of the Company; the appointment of Nan Zhang as the chief executive officer of the Company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.835 USD | -7.22% | -18.14% | +63.41% |
May. 28 | YS Biopharma Co., Ltd. will Change its Ticker to LSB from YS | CI |
May. 24 | YS Biopharma to Become LakeShore Biopharma, Ticker Symbol to Change to LSB From YS Starting May 28 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+63.41% | 157M | |
-2.29% | 89.87B | |
-3.95% | 37.57B | |
-13.07% | 32.75B | |
+63.05% | 26.47B | |
-22.14% | 14.25B | |
-7.96% | 12.99B | |
-9.33% | 11.93B | |
-46.33% | 10.84B | |
+5.77% | 9.11B |
- Stock Market
- Equities
- LSB Stock
- News LakeShore Biopharma Co., Ltd
- YS Biopharma Co., Ltd. Announces Chief Executive Officer Changes